Prevention of bleeding and hemorrhagic complications in surgical patients with inherited factor VII deficiency

• Published in: Blood coagulation & fibrinolysis Vol. 26; no. 3; pp. 324 - 330
• Main Authors: Wiszniewski, Adam, Szczepanik, Andrzej, Misiak, Andrzej, Bykowska, Ksenia, Szopiński, Piotr
• Format: Journal Article
• Language: English
• Published: England Copyright YEAR Wolters Kluwer Health, Inc. All rights reserved 01-04-2015
• Subjects: Adult; Aged; Blood Coagulation Factors - administration & dosage; Blood Coagulation Factors - therapeutic use; Blood Coagulation Tests; Blood Loss, Surgical - prevention & control; Elective Surgical Procedures; Factor VII Deficiency - complications; Factor VII Deficiency - drug therapy; Factor VIIa - administration & dosage; Factor VIIa - therapeutic use; Female; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Male; Middle Aged; Postoperative Care; Postoperative Hemorrhage - prevention & control; Preanesthetic Medication; Preoperative Care; Recombinant Proteins - administration & dosage; Recombinant Proteins - therapeutic use; Young Adult
• ISSN: 0957-5235; 1473-5733
• DOI: 10.1097/MBC.0000000000000258

Inherited factor VII (FVII) deficiency is a rare autosomal recessive hemorrhagic disorder. The major clinical symptoms includebleeding from the oral cavity, epistaxis, menorrhagia, spontaneous hemarthros, bleeding to the gastrointestinal tract and central nervous system, and perioperative bleeding. The aim of this study was to present our experience in preventing bleeding and hemorrhagic disorders in surgical patients with inherited FVII deficiency by using recombinant activated FVIIa (rFVIIa), and with prothrombin complex concentrates (PCCs). In 2002–2011, 17 patients with inherited FVII deficiency underwent surgery. Thirteen patients had isolated FVII deficiency below 10%, and four patients 10–25. To prevent bleeding and hemorrhagic complications, we administered small single doses of rFVIIa (Novo-Seven) at 12-h intervals to 15 patients on surgery day and on day 1 following surgery, then every 24 h; PCCs were administered (Prothromplex, Beriplex) to two patients. No symptoms of bleeding, hemorrhagic or thromboembolic complications were observed in the perioperative and 1-month observation period in surgical patients treated with rFVIIa. One patient treated with PCC (Prothromplex) developed distal deep vein thrombosis on postoperative day 7. The results suggest that small, single, every 12-h doses of rFVIIa (NovoSeven) and in next days after surgery one time every 24 h are well tolerated and effective for prevention of thromboembolic, bleeding and hemorrhagic complications in FVII-deficient patients. Antithrombotic prophylaxis with low-molecular-weight heparin should be applied in patients using PCCs.